Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Loredana Miglietta"'
Autor:
Matteo Lambertini, Paola Anserini, Valeria Fontana, Francesca Poggio, Giuseppina Iacono, Annalisa Abate, Alessia Levaggi, Loredana Miglietta, Claudia Bighin, Sara Giraudi, Alessia D’Alonzo, Eva Blondeaux, Davide Buffi, Francesco Campone, Domenico F. Merlo, Lucia Del Mastro
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To addr
Externí odkaz:
https://doaj.org/article/55e4d35012174cf8bceffd17a2b7a72e
Publikováno v:
Case Reports in Oncology, Vol 3, Iss 1, Pp 49-53 (2010)
Uterine smooth muscle tumors range from benign leiomyomata to low- and high-grade leiomyosarcomas. A leiomyosarcoma is a rare malignant smooth muscle tumor that infrequently metastasizes to the bone. In fact, initial presentation or recurrence as oss
Externí odkaz:
https://doaj.org/article/8b25af283b9b4054bf899dcead3c91ac
Autor:
Lucia Del Mastro, Matteo Lambertini, Michelino De Laurentiis, Teresa Gamucci, Marco Bruzzone, Piero Fregatti, Sabino De Placido, Eva Blondeaux, Loredana Miglietta, Francesco Cognetti, Claudia Bighin, Gim investigators, Francesca Poggio, E. Valle, Benedetta Conte, Francesco Boccardo, Cecilia Nisticò, Fabio Puglisi, Barbara Cardinali, Filippo Montemurro, Ornella Garrone, Marcello Ceppi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 136
Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Ita
Autor:
Matteo Lambertini, Alessia D'Alonzo, Beatrice Dozin, Lucia Del Mastro, Vincenzo Fontana, S. Giraudi, Marcello Ceppi, Francesca Poggio, A. Levaggi, Paolo Pronzato, Loredana Miglietta, Paolo Bruzzi, M. Vaglica, Claudia Bighin, G. Iacono
Publikováno v:
Oncotarget
// Claudia Bighin 1 , Beatrice Dozin 2 , Francesca Poggio 1 , Marcello Ceppi 2 , Paolo Bruzzi 2 , Alessia D’Alonzo 1 , Alessia Levaggi 1 , Sara Giraudi 1 , Matteo Lambertini 1 , Loredana Miglietta 1 , Marina Vaglica 1 , Vincenzo Fontana 2 , Giusepp
Autor:
Antonella Brunello, Matteo Lambertini, Fedro A. Peccatori, Lucia Del Mastro, Stefania Noli, Barbara Buonomo, Loredana Miglietta
Publikováno v:
Breast Care (Basel)
Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use of nonhormonal barrier contraception is recommended during tamoxifen treatment and up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::762f5c130cc510c82ca9384511db1ac5
https://europepmc.org/articles/PMC7204783/
https://europepmc.org/articles/PMC7204783/
Autor:
Andrea Fontana, Lucia Del Mastro, Matteo Lambertini, S. Pastorino, Chiara Molinelli, Giuseppe Naso, Francesca Poggio, Valentina Magri, Claudia Bighin, Giuseppe Buono, Grazia Arpino, Loredana Miglietta, Alessandra Fabi, Daniele Presti, Francesco Boccardo, Alessia D'Alonzo, Chiara Dellepiane, Francesco Cognetti, Silvia Mura, Eva Blondeaux, Benedetta Conte
Publikováno v:
Clinical breast cancer. 20(2)
Background T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data
Autor:
Matteo Lambertini, Lucia Del Mastro, S. Pastorino, Claudia Bighin, Silvia Mura, Alessia D'Alonzo, Francesco Boccardo, Giuseppe Buono, Giuseppe Naso, Daniele Presti, Francesco Cognetti, Alessandra Fabi, Valentina Magri, Chiara Dellepiane, Chiara Molinelli, Andrea Fontana, Grazia Arpino, Loredana Miglietta, Benedetta Conte, Eva Blondeaux, Francesca Poggio
Publikováno v:
The Breast. 48:S45
Autor:
A. Abate, Alberto Ballestrero, Maria Carolina Pescio, Matteo Lambertini, Benedetta Conte, G. Iacono, Lucia Del Mastro, Chiara Ferreccio, Alessia D'Alonzo, Paola Anserini, Francesco Boccardo, Eva Blondeaux, Chiara Dellepiane, Francesca Poggio, Loredana Miglietta, M. Vaglica, Elisa Zanardi, Valeria Fontana, Claudia Bighin, Claudia Massarotti
Background Despite the availability of different strategies for ovarian function and/or fertility preservation in young breast cancer patients candidates for chemotherapy, limited data are available on patients’ actual need of these options. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23db31a292a0665e14812cfd5920325
http://hdl.handle.net/11567/914058
http://hdl.handle.net/11567/914058
Autor:
Claudia Bighin, Lucia Del Mastro, Alessia Levaggi, Paola Anserini, G. Iacono, Valeria Fontana, Loredana Miglietta, Matteo Lambertini, Alessia D'Alonzo, Francesco Campone, A. Abate, Francesca Poggio, Domenico Franco Merlo, Eva Blondeaux, S. Giraudi, Davide Buffi
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
BMC Cancer
BMC cancer, 17 (1
BMC Cancer
BMC cancer, 17 (1
Background: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aff53c65ee8fa4bffebfa6ca101a10c
http://hdl.handle.net/11567/891505
http://hdl.handle.net/11567/891505
Autor:
Federico Castiglione, Tiziana Scotto, Andrea Michelotti, Paolo Pronzato, Claudia Bighin, Loredana Miglietta, Alessia Levaggi, Giovanna Cavazzini, Valeria Accortanzo, E. Landucci, Pierfranco Conte, S. Danese, Lucia Del Mastro, Francesca Adami, S. Pastorino, Paolo Bruzzi, Antonio Durando, Ornella Garrone, Margherita Piras
Publikováno v:
Breast cancer research and treatment. 155(1)
The study was designed to compare an anthracycline-containing regimen to a regimen combining both anthracycline and paclitaxel as adjuvant therapy for high-risk breast cancer patients. In this multicenter, randomized phase-III trial, node-positive ea